Please Wait
Applying Filters...
menu
    • menu
    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    Boai NKY Pharmaceuticals Ltd. is one of the largest global PVP suppliers.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    An Enquiry

    Nanjing Well is focused on R&D, production & sales of Pharmaceutical Excipients & Synthetic Lubricating base oils.

    Virtual Booth

    Contact Supplier

    Ever Pharma, highly specialized CDMO in producing complex injectables including high potency & controlled substances, suspensions, etc.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Pfizer Inc

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    EXCIPIENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital content

    Create Content with PharmaCompass, ask us

    INTERVIEW #SpeakPharma

    [Sponsored by another company]
    “We’re investing in next-gen CDMO & peptide building blocks infrastructure to support the evolving demands of complex therapies.”

    mic“We’re investing in next-gen CDMO & peptide building blocks infrastructure to support the evolving demands of complex therapies.”

    This week, SpeakPharma interviews Dr. Abdelaziz Toumi, Chief Executive Officer of Lupin Manufacturing Solutions (LMS). In this exclusive interview with PharmaCompass, Dr. Toumi discusses the evolving CDMO landscape, the shift toward complex therapies and growing peptide ecosystems along with LMS’s recent strategic investments in integrated CDMO and peptide building blocks infrastructure. As the industry convenes at DCAT Week, he highlights how LMS is positioning itself as a capability-driven CDMO partner for next-gen complex therapies.Dr. Toumi, The US has been taking several steps to reduce dependence on overseas pharmaceutical supply chains. How is Lupin Manufacturing Solutions (LMS) navigating these shifts?The framing of this debate as globalization versus reshoring misses what is actually happening. What we are seeing is a deliberate recalibration, a move from networks built purely for cost efficiency toward architectures that distribute risk more intelligently. That is a fundamentally different objective, and it changes what pharmaceutical companies expect from their manufacturing partners. What policymakers are pushing for, whether through the BIOSECURE Act or broader reshoring incentives, is a strategic allocation of manufacturing risk, and that is entirely rational.For LMS, this environment plays to our strengths. We have never positioned ourselves as a low-cost volume provider. Our competitive case is built on technical capability, regulatory reliability, and the ability to manage genuinely complex chemistry programs. Those attributes matter most to customers re-evaluating their supply relationships. Our investments in HPAPI containment, peptide building blocks, and integrated CDMO infrastructure reflect a deliberate commitment to being relevant precisely where complexity is highest. That is where we see sustained and growing demand, irrespective of how supply chain policy continues to evolve.How do you see the pharmaceutical landscape evolving over the next five years? How is LMS positioning itself to stay ahead of these changes?Five years from now, the defining feature of this industry will be the sheer scientific complexity embedded in pharmaceutical pipelines. Peptides, targeted oncology compounds, radiopharmaceuticals, these are not molecules you manufacture through conventional means. They demand deep process chemistry, specialized infrastructure, and partners who can genuinely co-develop solutions rather than simply execute a manufacturing order.That shift is changing how innovation-driven companies select their CDMO partners. Technical depth, regulatory track record, and the ability to navigate development risk have moved to the top of the evaluation criteria. At LMS, everything we are building right from our integrated CDMO block at Dabhasa to our HPAPI infrastructure at Vizag is calibrated to this reality. We are positioning to be a partner of choice and not just a transactional service provider.Could you provide an update on LMS’ oncology (HPAPI) manufacturing block in Visakhapatnam? How is it contributing to your CDMO strategy?Oncology manufacturing is one of the most technically exciting segments in the industry, and that complexity is only intensifying. As targeted therapies and antibody drug conjugates advance through pipelines, the demand for high-potency API capability delivered reliably, at global safety standards continues to grow.Our Vizag facility has been designed with that reality in mind, and that goes beyond containment engineering. It incorporates the process discipline, safety culture, and quality systems that high-potency manufacturing demands at every level of the organization. You cannot retrofit this kind of capability; it has to be purpose-built. What we have put in place is a platform that supports programs from early clinical development through commercial supply offering customers the continuity they need without transferring between sites as their programs mature. That continuity is a genuine competitive advantage.In December, LMS signed a strategic alliance with PolyPeptide Group AG to scale the global peptide supply chain. How will this collaboration strengthen your CDMO capabilities in the fast-growing peptide therapeutics segment?The rapid growth of peptide therapeutics, especially GLP1s, has fundamentally changed how the industry thinks about scale, reliability, and supply security. What was once a niche capability has become a core requirement, and customers are now looking for partners who can support the peptide value chain end-to-end, at a global scale.LMS’s strategy is built around serving the entire peptide market and establishing a globally competitive platform over the next three to five years, rooted in India, positioning itself as a credible partner amidst the China+1 strategy, capable of supporting both innovators and large pharmaceutical companies. The strategic alliance with PolyPeptide Group fits naturally within this vision allowing us to complement our own capabilities with additional synthesis depth and geographic flexibility, particularly for customers seeking resilient, diversified supply chains.LMS brings deep process chemistry expertise, a growing peptide intermediates and building blocks platform at Dabhasa, and strong regulatory execution. Importantly, as part of the Lupin group, we are also able to offer downstream drug product manufacturing capabilities spanning oral formulations as well as sterile injectables, including vials and drug-device delivery systems, which are increasingly critical as peptide programs move rapidly from development to commercial scale.Together, this integrated approach allows us to support customers across the full lifecycle, from peptide intermediates and APIs through to finished dosage forms. In a market defined by speed, scale, and supply assurance, this breadth of capability positions LMS to emerge as one of the leading global players in peptide CDMO services.As the industry convenes at DCAT Week, what is LMS bringing to the table this year?This year is about laying the foundations for LMS’s next phase of growth, particularly in complex and high value modalities. Strategically, our focus is on building the capabilities required to support emerging oncology and peptide adjacent platforms, while preparing for commercial scale-up over the next 18-24 months.On the technology side, LMS already has strong R&D capabilities across peptides, payloads and linkers, bioconjugation, and high potent compounds. These capabilities allow us to engage with customers early in development, solve complex chemistry challenges, and support rapid transition from discovery into development programs. Building on this base, we are progressing plans to establish commercial-scale GMP capacities in payload-linker synthesis and bioconjugation, including the development of a dedicated GMP facility in Vizag. This is a critical step for us as more antibody drug conjugates and related platforms move toward late-stage development and commercialization.Equally important is how we engage with customers. Alongside traditional CDMO models, we are increasingly offering alternative business models such as dedicated facilities, long-term capacity commitments, and guaranteed supply arrangements designed to address customers’ growing concerns around security, scalability, and speed to market. Overall, the year ahead is about execution including strengthening our R&D engine, advancing commercial-scale infrastructure, and deepening customer partnerships so that LMS is well positioned to support complex programs as they move into clinical and commercial reality.LMS has articulated its ambition to emerge as a trusted global CDMO partner with next-generation manufacturing capabilities and scientific agility. How would you assess your progress toward that goal?Trusted partnerships are earned over time, and I am clear-eyed about that. What I can say with confidence is that the strategic choices we have made over the past year have been the right ones, and the investment portfolio we have assembled aligns with direction the industry is heading.The development of our integrated CDMO block at Dabhasa, the scaling of peptide building blocks capabilities, the Vizag HPAPI facility, the PolyPeptide alliance, these reflect a coherent long-term strategy. What continues to occupy my attention most is execution. Infrastructure sets the stage, but it is our science, our quality systems, and our people that customers will ultimately judge us by. That work is ongoing, and it is where I spend most of my time.Could you update us on LMS’ green manufacturing initiatives? How is sustainability being integrated into your operations and facilities?Sustainability has shifted from a compliance requirement to a genuine competitive dimension, and I think that shift is permanent. Customers, investors, and regulators are asking harder questions, and organizations treating it just as a reporting exercise will find themselves at a disadvantage.Our approach remains grounded in the belief that durable environmental improvement comes from process intelligence. When you optimize synthesis routes for atom economy, reduce solvent intensity, and engineer waste out at the design stage, you improve sustainability and manufacturing economics simultaneously. These are not competing priorities. We are embedding green chemistry principles across our development workflows and investing in solvent recovery and waste management infrastructure. Our parent organization Lupin Limited was recently recognized among the top 1% of companies worldwide in the S&P Global Corporate Sustainability Assessment (CSA) attaining an overall score of 91 out of 100 establishing itself as the leading pharmaceutical company globally, and the leader across all sectors in India, surpassing both Indian and international peers which underscores our commitment.

    Impressions: 2641

    subscribeSubscribe

    https://www.pharmacompass.com/speak-pharma/we-re-investing-in-next-gen-cdmo-peptide-building-blocks-infrastructure-to-support-the-evolving-demands-of-complex-therapies

    PharmaCompass
    24 Mar 2026
    Share info Share

    VLOG #PharmaReel

    [Sponsored by another company]

    ReelPharmaYour End-to-End API PartnerYour End-to-End API Partner

    Your End-to-End API Partner
    Your End-to-End API Partner

    reelYour End-to-End API Partner

    This PharmaReel spotlights Coral Drugs, your trusted partner in end-to-end API manufacturing. Specializing in high-quality APIs with a strong focus on steroids and hormones, Coral Drugs is a vertically integrated, cGMP-certified international company committed to delivering excellence at every stage of manufacturing, backed by quality, consistency, and reliability you can trust.

    Impressions: 297

    read-more

    DATA COMPILATION #PharmaFlow

    [Sponsored by another company]
    Prostaglandin market to cross US$ 1.27 bn by 2035; Liquidia’s Yutrepia okayed for pulmonary hypertension

    Prostaglandin market to cross US$ 1.27 bn by 2035; Liquidia’s Yutrepia okayed for pulmonary hypertension

    Prostaglandins are natural fatty acid compounds produced by the human body. They are made from a type of fat known as arachidonic acid and act like messengers, controlling many functions such as inflammation, blood flow, muscle contraction, and fluid drainage in the eye. Prostaglandin APIs are synthetic (lab-made) versions of natural prostaglandins that are used to create medicines. Prostaglandin-based medicines are used in obstetrics and gynecology, gastroenterology, urology, and cosmetics, and their use is also being explored in certain cardiovascular and respiratory conditions. One of the largest and most important uses of prostaglandin APIs is in ophthalmology (eye care), where they are used as first-line therapy for open-angle glaucoma (a chronic, progressive eye disease) and ocular hypertension (a condition where pressure inside the eye is consistently higher than normal). In ophthalmic applications, these drugs usually serve as prodrugs – inactive in the formulation but converted into their active form after entering the eye.According to estimates, the global prostaglandin market is valued at US$ 0.63 billion in 2025 and is poised to grow from US$ 0.68 billion in 2026 to US$ 1.27 billion by 2035, growing at a CAGR of 7.1 percent between 2026 and 2035.Prostaglandin API manufacturing is a highly specialised field, with only a few experienced manufacturers. Companies such as EUROAPI, Cayman Pharma, Chirogate International, Kyowa Pharma Chemical, Everlight Chemical, and Yonsung Fine Chemicals are key players with strong capabilities in complex chemistry.FDA allows Glaukos’ iDose TR to be re-administered for treating eye diseases; approves Liquidia’s Yutrepia The prostaglandin market continues to see steady regulatory activity and innovations. In ophthalmology, Glaukos Corporation’s iDose TR received a labelling supplement from the US Food and Drug Administration (FDA) that allows for re-administration of the medication indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). The intracameral implant was originally approved in December 2023 for single use. This update was supported by long-term safety data demonstrating good tolerability in patients with OAG and OHT. Similarly, Santen Pharmaceutical secured manufacturing and marketing approval in Japan for Setaneo (sepetaprost) ophthalmic solution 0.002% in August 2025 for the treatment of glaucoma and OHT. In April 2025, Santen also received approval in China for Tapcom (tafluprost + timolol maleate), a preservative-free fixed-dose combination therapy that lowers intraocular pressure (IOP) in patients with OAG and OHT.Beyond ophthalmology, prostaglandin APIs are also driving advancements in respiratory care. Liquidia Corporation received FDA approval in May 2025 for Yutrepia (treprostinil) inhalation powder for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). While PAH is a serious and progressive disease where blood pressure in the lung arteries rises, causing them to narrow and harden, PH-ILD is a serious complication in which high blood pressure develops in the lung arteries due to lung scarring. Yutrepia is the first and only prostacyclin dry-powder formulation enabled by Liquidia’s proprietary technology.  Access the Interactive Dashboard on Prostaglandin Developments (Free Excel Available)Nicox’s drug scores phase 3 win in glaucoma, OHT; United seeks expanded approval for Tyvaso to treat pulmonary fibrosisInnovation in prostaglandins is increasingly focused on enhanced efficacy and sustained drug delivery. French ophthalmology company Nicox has reported positive phase 3 results for its ophthalmic solution NCX 470, demonstrating consistent lowering of intraocular pressure in OAG and OHT. Nicox is likely to submit a new drug application for NCX 470 sometime soon, with a potential approval and launch expected in 2027.Meanwhile, US-based SpyGlass Pharma is advancing sustained-release innovation through intraocular lens (IOL)-based and ring-based drug delivery systems. Its Bimatoprost Drug Pad–Intraocular Lens (BIM-IOL) system (currently in phase 3 trials) integrates drug delivery with cataract surgery to enable sustained therapy for up to three years. The company is also developing a preclinical Bimatoprost Drug Ring System (BIM-DRS) designed for similarly extended drug release. In respiratory indications, Insmedis progressing treprostinil palmitil inhalation powder through phase 3 trials for PH-ILD, as well as for idiopathic pulmonary fibrosis and PAH.Additionally, United Therapeutics is expanding the clinical scope of Tyvaso DPI (treprostinil). Following its global approval in 2022 for PAH, the therapy is now under regulatory review in the US and Canada for progressive pulmonary fibrosis and idiopathic pulmonary fibrosis.  Access the Interactive Dashboard on Prostaglandin Developments (Free Excel Available)Glaukos sets up new R&D facility in Alabama, Inke acquires Pharmanoid to strengthen presence in prostaglandins Several players are expanding capacities due to rising demand across ophthalmology. Glaukos Corporation is setting up a new research, development, and manufacturing facility in Huntsville, Alabama. The planned 200,000 square-foot site, to be built on a 25-acre campus in Cummings Research Park, envisages an investment of over US$ 80 million. Expected to be completed by 2030, the facility is designed to augment the company’s existing infrastructure and support long-term growth, particularly in ophthalmic therapies including sustained-release drug delivery systems.EUROAPIis undertaking a significant capacity expansion at its Budapest site. The company has committed €50 million (US$ 54.8 million) to install a new state-of-the-art production plant focused on prostaglandins. The project aims to debottleneck existing operations and introduce new multi-purpose manufacturing equipment, ultimately more than doubling the site’s prostaglandin production capacity by 2027. The expansion will also strengthen EUROAPI’s highly potent API (HPAPI) capabilities.Alongside capacity additions by established players, the market is also witnessing consolidation and capability expansion through acquisitions. For instance, Essential Pharma acquired Ventavis (iloprost trometamol) from Bayer AG, including rights to the accompanying Breelib nebuliser delivery technology. Ventavis, a prostacyclin analogue, is a well-established treatment for adult patients with primary pulmonary hypertension.Inke strengthened its presence in ophthalmology-focused high-potency APIs (HPAPIs), including prostaglandins, through the acquisition of Pharmanoid in December 2025. Backed by regulatory approvals across 25+ countries, Pharmanoid enhances Inke’s capabilities in complex API production and supports its ambition to build a leading European platform for advanced API development and manufacturing. The Barcelona facility is capable of producing and handling APIs across all potency levels while adhering to SafeBridge Scale OEB4 (Occupational Exposure Band 4) containment protocols, a classification for high-potency substances requiring strict controls to limit occupational exposure.With more than two decades of experience, Inke is recognized for innovating and manufacturing high-quality APIs, delivering expertise, safety, and excellence across inhalation, CNS, and ophthalmic therapies, while supporting pharmaceutical companies worldwide. The ophthalmic API commercial portfolio includes bimatoprost, latanoprost, tafluprost, and travoprost, while the next-generation prostaglandin analog pipeline includes bimatoprost grenod and latanoprostene bunod.  Access the Interactive Dashboard on Prostaglandin Developments (Free Excel Available)Our viewInnovation is guiding the prostaglandins market towards long-acting, sustained-release formulations and novel delivery systems. These innovations are driving steady growth in prostaglandins, while capacity expansions are strengthening capabilities in complex and highly potent APIs. Overall, this remains a niche but important market to watch. 
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 2243

    https://www.pharmacompass.com/radio-compass-blog/prostaglandin-market-to-cross-us-1-27-bn-by-2035-liquidia-s-yutrepia-okayed-for-pulmonary-hypertension

    #PharmaFlow by PHARMACOMPASS
    14 May 2026
    Share Share

    NEWS #PharmaBuzz

    [Sponsored by another company]read-more
    read-more
    Innovent Biologics, Pfizer Enter Global Oncology Collaboration
    Innovent Biologics, Pfizer Enter Global Oncology Collaboration

    30 May 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/innovent-biologics-and-pfizer-enter-global-strategic-collaboration-to-accelerate-development-of-innovative-oncology-medicines-302785085.html

    PR NEWSWIRE
    30 May 2026
    Share Share
    Pfizer Wins Singapore Trademark Dispute With Merck
    Pfizer Wins Singapore Trademark Dispute With Merck

    24 May 2026

    // STRAITSTIMES

    https://www.straitstimes.com/business/pfizer-wins-singapore-trademark-dispute-with-merck-over-vaccine-brand

    STRAITSTIMES
    24 May 2026
    Share Share
    #ASCO26: New VEGF Bispecific Data From BioNTech-BMS, Pfizer-3SBio
    #ASCO26: New VEGF Bispecific Data From BioNTech-BMS, Pfizer-3SBio

    21 May 2026

    // ENDPOINTS

    https://endpoints.news/new-data-released-for-vegf-bispecifics-from-biontech-bms-pfizer-3sbio/

    ENDPOINTS
    21 May 2026
    Share Share
    Pfizer Advances Pediatric Pneumococcal Vaccine After Phase 2 Win
    Pfizer Advances Pediatric Pneumococcal Vaccine After Phase 2 Win

    20 May 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260520512448/en/Pfizer-Advances-Pivotal-Pediatric-Pneumococcal-Vaccine-Program-Following-Strong-Positive-Phase-2-Results

    BUSINESSWIRE
    20 May 2026
    Share Share
    Sarah Cannon and Pfizer Announce Strategic Oncology Collaboration
    Sarah Cannon and Pfizer Announce Strategic Oncology Collaboration

    20 May 2026

    // PRESS RELEASE

    https://www.scri.com/news/sarah-cannon-research-institute-announces-strategic--oncology-research-collaboration-with-pfizer/

    PRESS RELEASE
    20 May 2026
    Share Share
    Pfizer Shot Shows Robust Immune Response in Trial
    Pfizer Shot Shows Robust Immune Response in Trial

    20 May 2026

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/pfizers-pneumococcal-shot-shows-stronger-immune-response-mid-stage-trial-2026-05-20/

    REUTERS
    20 May 2026
    Share Share
    Contact Pfizer Inc and get a quotation

    Pfizer Inc is a supplier offers 265 products (APIs, Excipients or Intermediates).

    Find Betamethyl Epoxide bulk with DMF, JDMF offered by Pfizer Inc

    Find Epoprostenol Sodium bulk with DMF, JDMF offered by Pfizer Inc

    Find Methylprednisolone bulk with DMF, CEP offered by Pfizer Inc

    Find Prednisolone bulk with JDMF offered by Pfizer Inc

    Find Dexamethasone bulk with JDMF offered by Pfizer Inc

    Find Estradiol Cypionate bulk with DMF offered by Pfizer Inc

    Find Estramustine Sodium Phosphate bulk with DMF offered by Pfizer Inc

    Find Methylprednisolone Acetate bulk with DMF offered by Pfizer Inc

    Find Alprazolam bulk with CEP offered by Pfizer Inc

    Find Betamethasone bulk offered by Pfizer Inc

    Find Betamethasone Valerate bulk offered by Pfizer Inc

    Find Cabergoline bulk offered by Pfizer Inc

    Find Calicheamicin bulk with DMF offered by Pfizer Inc

    Find CAS 50-28-2 bulk offered by Pfizer Inc

    Find Chlormadinone Acetate bulk with JDMF offered by Pfizer Inc

    Find Clindamycin Palmitate bulk with DMF offered by Pfizer Inc

    Find Clindamycin Phosphate bulk with DMF offered by Pfizer Inc

    Find Cortisone bulk offered by Pfizer Inc

    Find Diflorasone bulk offered by Pfizer Inc

    Find Dinoprostone bulk with DMF offered by Pfizer Inc

    Find Doxorubicin Hydrochloride bulk with DMF offered by Pfizer Inc

    Find Flumethasone bulk offered by Pfizer Inc

    Find Fluoxymesterone bulk offered by Pfizer Inc

    Find Glipizide bulk with DMF offered by Pfizer Inc

    Find Hydrocortisone Sodium Succinate bulk with CEP offered by Pfizer Inc

    Find Lincomycin Hydrochloride bulk with DMF offered by Pfizer Inc

    Find Megestrol Acetate bulk with DMF offered by Pfizer Inc

    Find Methylprednisolone bulk offered by Pfizer Inc

    Find Methylprednisolone Hemisuccinate bulk with CEP offered by Pfizer Inc

    Find Piroxicam bulk with CEP offered by Pfizer Inc

    Find Prednisolone Acetate bulk offered by Pfizer Inc

    Find Progesterone bulk with JDMF offered by Pfizer Inc

    Find Triamcinolone bulk offered by Pfizer Inc

    Find Triamcinolone Acetonide bulk offered by Pfizer Inc

    Find Triamcinolone Diacetate bulk offered by Pfizer Inc

    Find 9-Aminocamptothecin bulk offered by Pfizer Inc

    Find Acecainide bulk offered by Pfizer Inc

    Find Acivicin bulk offered by Pfizer Inc

    Find Amphotericin B bulk offered by Pfizer Inc

    Find Ampicillin Sodium bulk offered by Pfizer Inc

    Find Ampicillin Trihydrate bulk offered by Pfizer Inc

    Find Arginine Vasopressin bulk offered by Pfizer Inc

    Find Arlitene bulk offered by Pfizer Inc

    Find Aspirin bulk offered by Pfizer Inc

    Find Atorvastatin bulk offered by Pfizer Inc

    Find Bacampicillin bulk offered by Pfizer Inc

    Find Bacitracin Zinc bulk offered by Pfizer Inc

    Find Benzylpenicillin Sodium bulk offered by Pfizer Inc

    Find Betamethasone Benzoate bulk offered by Pfizer Inc

    Find Betamethasone Dipropionate bulk offered by Pfizer Inc

    Find Carbenicillin Indanyl bulk offered by Pfizer Inc

    Find Carboxylic Acid bulk offered by Pfizer Inc

    Find CAS 71-58-9 bulk offered by Pfizer Inc

    Find Cefixime bulk offered by Pfizer Inc

    Find Cefoperazone Sodium bulk offered by Pfizer Inc

    Find Chloramphenicol Palmitate bulk offered by Pfizer Inc

    Find Chloramphenicol Succinate Acid bulk offered by Pfizer Inc

    Find Chlorhexidine Gluconate bulk offered by Pfizer Inc

    Find Chlorpropamide bulk offered by Pfizer Inc

    Find Chlortetracycline Hydrochloride bulk offered by Pfizer Inc

    Find Chondroitin Sulfate Sodium bulk offered by Pfizer Inc

    Find Clindamycin Hydrochloride bulk offered by Pfizer Inc

    Find Clindamycin Phosphate bulk offered by Pfizer Inc

    Find Cycloheximide bulk offered by Pfizer Inc

    Find Cytarabine bulk offered by Pfizer Inc

    Find Dacarbazine bulk offered by Pfizer Inc

    Find Deferoxamine Mesylate bulk offered by Pfizer Inc

    Find Demeclocycline Hydrochloride bulk offered by Pfizer Inc

    Find Diphenhydramine bulk offered by Pfizer Inc

    Find Doxorubicin Hydrochloride bulk offered by Pfizer Inc

    Find Doxycycline Hyclate bulk offered by Pfizer Inc

    Find Edoxudin bulk offered by Pfizer Inc

    Find Erythromycin bulk offered by Pfizer Inc

    Find Erythromycin Stearate bulk offered by Pfizer Inc

    Find Estradiol bulk offered by Pfizer Inc

    Find Estramustine Sodium Phosphate bulk offered by Pfizer Inc

    Find Ethinyl Estradiol bulk offered by Pfizer Inc

    Find Etodolac bulk offered by Pfizer Inc

    Find Exemestane bulk offered by Pfizer Inc

    Find Fedotozine Tartrate bulk offered by Pfizer Inc

    Find Fludrocortisone Acetate bulk offered by Pfizer Inc

    Find Fluocinolone Acetonide bulk offered by Pfizer Inc

    Find Fluorometholone bulk offered by Pfizer Inc

    Find Hydrocortisone bulk offered by Pfizer Inc

    Find Hydrocortisone Sodium Succinate bulk offered by Pfizer Inc

    Find Hydrogen Peroxide bulk offered by Pfizer Inc

    Find Hydroxyprogesterone Caproate bulk offered by Pfizer Inc

    Find Ibuprofen bulk offered by Pfizer Inc

    Find Idarubicin Hydrochloride bulk offered by Pfizer Inc

    Find Lysergic Acid bulk offered by Pfizer Inc

    Find Lysine Hydrochloride bulk offered by Pfizer Inc

    Find Meclofenamic Acid bulk offered by Pfizer Inc

    Find Medroxyprogesterone Acetate bulk offered by Pfizer Inc

    Find Medrysone bulk offered by Pfizer Inc

    Find Menogarol bulk offered by Pfizer Inc

    Find Metergoline bulk offered by Pfizer Inc

    Find Methacycline Hydrochloride bulk offered by Pfizer Inc

    Find Methaqualone bulk offered by Pfizer Inc

    Find Methotrexate bulk offered by Pfizer Inc

    Find Methyl Testosterone bulk offered by Pfizer Inc

    Find Methylprednisolone Hemisuccinate bulk offered by Pfizer Inc

    Find Minocycline Hydrochloride bulk offered by Pfizer Inc

    Find Minoxidil bulk offered by Pfizer Inc

    Find Mithramycin bulk offered by Pfizer Inc

    Find Neomycin Sulfate bulk offered by Pfizer Inc

    Find Nicotine bulk offered by Pfizer Inc

    Find Nystatin bulk offered by Pfizer Inc

    Find Olsalazine bulk offered by Pfizer Inc

    Find Oxytetracycline Calcium bulk offered by Pfizer Inc

    Find Oxytetracycline Dihydrate bulk offered by Pfizer Inc

    Find Oxytetracycline Hydrochloride bulk offered by Pfizer Inc

    Find Penicillin G Benzathine bulk offered by Pfizer Inc

    Find Penicillin G Procaine bulk offered by Pfizer Inc

    Find Penicillin V Potassium bulk offered by Pfizer Inc

    Find Pentostatin bulk offered by Pfizer Inc

    Find Phenytoin Sodium bulk offered by Pfizer Inc

    Find Piperacillin Sodium bulk offered by Pfizer Inc

    Find Polyethylene Glycol Monostearate bulk offered by Pfizer Inc

    Find Prednisolone bulk offered by Pfizer Inc

    Find Prednisolone Sodium Phosphate bulk offered by Pfizer Inc

    Find Prednisone bulk offered by Pfizer Inc

    Find Prednisone Acetate bulk offered by Pfizer Inc

    Find Reserpine bulk offered by Pfizer Inc

    Find Rifabutin bulk offered by Pfizer Inc

    Find Silicon Dioxide API bulk offered by Pfizer Inc

    Find Spectinomycin HCl bulk offered by Pfizer Inc

    Find Streptomycin bulk offered by Pfizer Inc

    Find Testolactone bulk offered by Pfizer Inc

    Find Testosterone Enanthate bulk offered by Pfizer Inc

    Find Tetracycline bulk offered by Pfizer Inc

    Find Tetracycline Hydrochloride bulk offered by Pfizer Inc

    Find Tinidazole bulk offered by Pfizer Inc

    Find Tirilazad bulk offered by Pfizer Inc

    Find Tolbutamide bulk offered by Pfizer Inc

    Find Tranexamic Acid bulk offered by Pfizer Inc

    Find Treprostinil Sodium bulk offered by Pfizer Inc

    Find Triazolam bulk offered by Pfizer Inc

    Find Troleandomycin bulk offered by Pfizer Inc

    Find Vancomycin Hydrochloride bulk offered by Pfizer Inc

    Find Vidarabine bulk offered by Pfizer Inc

    Find Viomycin Sulfate bulk offered by Pfizer Inc

    Find Zinc Gluconate API bulk offered by Pfizer Inc

    Find FACILITIES & GENERAL OPERATING PROCEDURES (SANDY, UTAH LOCATION) bulk offered by Pfizer Inc

    Find CLINICAL INVESTIGATION --CI 442 bulk offered by Pfizer Inc

    Find AT THE CHRISTIANSTED, ST. CROIX LOCATION bulk offered by Pfizer Inc

    Find FACILITIES AND CONTROLS IN WEST SUSSEX, U.K. bulk offered by Pfizer Inc

    Find SOLKETAL(GLYCEROL 1,2 - ISOPROPYLIDENE ETHER) bulk offered by Pfizer Inc

    Find GEN. INFO APPLICABLE TO THE FINE CHEMICAL OPERATIONS bulk offered by Pfizer Inc

    Find MANUFACTURING ,PACKAGING AND CONTROLS PROCEDURES-THIS IS A VET MED D bulk offered by Pfizer Inc

    Find MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN HILLEROD, DENMARK. bulk offered by Pfizer Inc

    Find ANTIBIOTIC GENERAL INFORMATION bulk offered by Pfizer Inc

    Find QUALITY CONTROL INFORMATION FOR NDA ANTIBIOTIC bulk offered by Pfizer Inc

    Find U-32, 070E (25-HYDROXYCHOLECALCIFEROL) bulk offered by Pfizer Inc

    Find FACILITY AND OPERATING PROCEDURES AT THE BRUNNA FACILITY IN KUNGSANGEN, SWEDEN bulk offered by Pfizer Inc

    Find IODODOXORUBICIN HCL FOR INJECTION bulk offered by Pfizer Inc

    Find MANFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN JOHANNESHOV, SWEDEN. bulk offered by Pfizer Inc

    Find MANUFACTURING SITE, FACILITIES, OPERATING PROCEDURES AND PERSONNEL IN UPPSALA, SWEDEN. bulk offered by Pfizer Inc

    Find VIRAL AND BACTERIAL VACCINE bulk offered by Pfizer Inc

    Find BIZELESIN (U-77779) DRUG SUBSTANCE bulk offered by Pfizer Inc

    Find W 3361, A LIQUID ANTACID FORMULATION ---CHITOSAN ANTACID bulk offered by Pfizer Inc

    Find MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN MILAN, ITALY. bulk offered by Pfizer Inc

    Find MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES bulk offered by Pfizer Inc

    Find CLINICAL INVESTIGATION--CI-383 bulk offered by Pfizer Inc

    Find MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN GWENT, UNITED KINGDOM. bulk offered by Pfizer Inc

    Find CLINICAL INVESTIGATIONS--CI 400 AND 421 bulk offered by Pfizer Inc

    Find PERSONNEL, FACILITIES & GENERAL OPERATING PROCEDURES bulk offered by Pfizer Inc

    Find CLINICAL INVESTIGATION--CI-446 bulk offered by Pfizer Inc

    Find STYRENE - MALEIC ACID COPOLYMER-TOXIC. DATA, CLIN REPTS & PHYSI CHARAC bulk offered by Pfizer Inc

    Find MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN PARSIPPANY, NEW JERSEY. bulk offered by Pfizer Inc

    Find NSC-51173, (U-10955)--5A-ANDROSTAN-3-ONE,2A-FLUORO-17B-HYDROXY bulk offered by Pfizer Inc

    Find 1-DESOXYEPHEDRINE bulk offered by Pfizer Inc

    Find PACKAGING OPERATION bulk offered by Pfizer Inc

    Find PERSONNEL, FACILS & GEN OPER PROCEDS AT THE LITITZ, PA FACILITY bulk offered by Pfizer Inc

    Find FACILS. & CONTROLS LOCATED IN FJARDO, PUERTO RICO FACILITY bulk offered by Pfizer Inc

    Find COMBINED ADRENAL HORMONE ANTIBIOTIC THERAPY bulk offered by Pfizer Inc

    Find CI -404 - ACTINOBOLIN SULFATE bulk offered by Pfizer Inc

    Find 17-DESOXY OXIDO bulk offered by Pfizer Inc

    Find 16-METHYLDIOLONE ACETATE AND S.D. VII) 9(11)-ANHYDRO-16a METHYLPREDNIS bulk offered by Pfizer Inc

    Find FACILITY AND OPERATING PROCEDURES IN STOCKHOLM, SWEDEN bulk offered by Pfizer Inc

    Find IODODOXORUBICIN HCL BULK DRUG SUBSTANCE bulk offered by Pfizer Inc

    Find MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN BRISTOL, TENNESSEE. bulk offered by Pfizer Inc

    Find MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN ARNPRIOR, ONTARIO, CANADA. bulk offered by Pfizer Inc

    Find POLYMYXIN METHANE SULFONATE FOR TREAT. OF DISEASE IN POULTRY (VET) bulk offered by Pfizer Inc

    Find FACILITY, PERSONNEL AND OPERATING PROCEDURES IN STOCKHOLM, SWEDEN bulk offered by Pfizer Inc

    Find MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN UPPSALA, SWEDEN. bulk offered by Pfizer Inc

    Find CLINICAL INVESTIGATION--CI-462 bulk offered by Pfizer Inc

    Find BULK CHEMICALS , METHOD OF PREPARATION bulk offered by Pfizer Inc

    Find CLINICAL INVESTIGATION--CI 344 bulk offered by Pfizer Inc

    Find QUALIFICATIONS OF PARKE, DAVIS & CO. RESEARCH PERSONNEL bulk offered by Pfizer Inc

    Find CLINICAL INVESTIGATION--CI423 bulk offered by Pfizer Inc

    Find G, PROCESS & PACK OF INDS IN MORRIS PLAINS, NJ FACIL (710 TABOR RD) bulk offered by Pfizer Inc

    Find CLINICAL INVESTIGATION 461 bulk offered by Pfizer Inc

    Find CAPSULE PLANT OPERATION AT THE DETROIT, MICHIGAN FACILITY bulk offered by Pfizer Inc

    Find MANUFACTURING FACILITIES IN COLUMBUS, OHIO bulk offered by Pfizer Inc

    Find OLEANSOMYCIN AND COCCIDIOSTATS IN POULTRY FEED bulk offered by Pfizer Inc

    Find PELLETHANE MDI BASED URETHANE ELASTOMER bulk offered by Pfizer Inc

    Find WARNER-LAMBERT, CAPS PLANT OPER, BROCKVILLE, ONTARIO, CAN FACILITY bulk offered by Pfizer Inc

    Find ARA-CYTIDINE 5 - BENZOATE (U - 32,072E) bulk offered by Pfizer Inc

    Find (U-31, 583) 1-B-D-ARABINOFURANOSYLCYTOSINE 5'-PALMITATE bulk offered by Pfizer Inc

    Find FACILITY AND OPERATING PROCEDURES IN STRANGNAS, SWEDEN bulk offered by Pfizer Inc

    Find MANUFACTURING SITE FACILITIES OPERATING PROCEDURES AND PERSONNEL OF THE GS/API PROCESS R&D PLANT IN NERVIANO ITALY bulk offered by Pfizer Inc

    Find HYDROXY ACID bulk offered by Pfizer Inc

    Find METHODS, FACILITIES AND CONTROLS bulk offered by Pfizer Inc

    Find METHODS, FACILS & CONTRLS bulk offered by Pfizer Inc

    Find MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES OF LARGE VOLUME PARENTERALS IN GLASS BOTTLES IN UPPSALS, SWEDEN. bulk offered by Pfizer Inc

    Find FACILITIES, PERSONNEL & EQUIPMENT IN SANDWICH, KENT, ENGLAND bulk offered by Pfizer Inc

    Find VIRAL AND BACTERIAL VACCINES bulk offered by Pfizer Inc

    Find CLINICAL INVESTIGATION-- CI-395 bulk offered by Pfizer Inc

    Find PERSONNEL FACILITIES AND OPERATING PROCEDURE bulk offered by Pfizer Inc

    Find CLINICAL INVESTIGATION--CI 384 bulk offered by Pfizer Inc

    Find Abrocitinib bulk offered by Pfizer Inc

    Find Alprostadil bulk offered by Pfizer Inc

    Find Amlodipine Besylate bulk offered by Pfizer Inc

    Find Anidulafungin bulk offered by Pfizer Inc

    Find Axitinib bulk offered by Pfizer Inc

    Find Azithromycin bulk offered by Pfizer Inc

    Find Azithromycin Dihydrate bulk offered by Pfizer Inc

    Find Bosutinib Monohydrate bulk offered by Pfizer Inc

    Find Celecoxib bulk offered by Pfizer Inc

    Find Conjugated Estrogens bulk offered by Pfizer Inc

    Find Crisaborole bulk offered by Pfizer Inc

    Find Crizotinib bulk offered by Pfizer Inc

    Find Dacomitinib bulk offered by Pfizer Inc

    Find Desvenlafaxine Succinate bulk offered by Pfizer Inc

    Find Dexamethasone bulk offered by Pfizer Inc

    Find Dexamethasone Sodium Phosphate bulk offered by Pfizer Inc

    Find Dinoprost Tromethamine bulk offered by Pfizer Inc

    Find Doxazosin Mesylate bulk offered by Pfizer Inc

    Find Eletriptan Hydrobromide bulk offered by Pfizer Inc

    Find Ertugliflozin bulk offered by Pfizer Inc

    Find Estradiol Benzoate bulk offered by Pfizer Inc

    Find Fesoterodine bulk offered by Pfizer Inc

    Find Fluconazole bulk offered by Pfizer Inc

    Find Hydrocortisone Acetate bulk offered by Pfizer Inc

    Find Latanoprost bulk offered by Pfizer Inc

    Find Linezolid bulk offered by Pfizer Inc

    Find Lorlatinib bulk offered by Pfizer Inc

    Find Nirmatrelvir bulk offered by Pfizer Inc

    Find Novobiocin Sodium bulk offered by Pfizer Inc

    Find Opiranserin Hydrochloride bulk offered by Pfizer Inc

    Find Palbociclib bulk offered by Pfizer Inc

    Find Pegvisomant bulk offered by Pfizer Inc

    Find Phenytoin bulk offered by Pfizer Inc

    Find Prazosin Hydrochloride bulk offered by Pfizer Inc

    Find Pregabalin bulk offered by Pfizer Inc

    Find Progesterone bulk offered by Pfizer Inc

    Find Sertraline Hydrochloride bulk offered by Pfizer Inc

    Find Sildenafil Citrate bulk offered by Pfizer Inc

    Find Spectinomycin bulk offered by Pfizer Inc

    Find Sunitinib bulk offered by Pfizer Inc

    Find Tafamidis bulk offered by Pfizer Inc

    Find Taliglucerase Alfa bulk offered by Pfizer Inc

    Find Testosterone bulk offered by Pfizer Inc

    Find Testosterone Cypionate bulk offered by Pfizer Inc

    Find Testosterone Propionate bulk offered by Pfizer Inc

    Find Testosterone Undecanoate bulk offered by Pfizer Inc

    Find Tigecycline bulk offered by Pfizer Inc

    Find Tofacitinib Citrate bulk offered by Pfizer Inc

    Find Tolterodine Tartrate bulk offered by Pfizer Inc

    Find Trenbolone bulk offered by Pfizer Inc

    Find Varenicline Tartrate bulk offered by Pfizer Inc

    Find Voriconazole bulk offered by Pfizer Inc

    Find Ziprasidone Hydrochloride bulk offered by Pfizer Inc

    Find Ziprasidone Mesylate bulk offered by Pfizer Inc

    Find Rittlesitinib tosylate bulk offered by Pfizer Inc

    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.